Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) has been assigned an average recommendation of “Moderate Buy” from the five ratings firms that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $38.3333.

Several analysts have commented on the stock. Lucid Cap Mkts upgraded shares of Eloxx Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, August 20th. Weiss Ratings started coverage on Eloxx Pharmaceuticals in a report on Friday, August 14th. They issued a “sell (d)” rating for the company. Lifesci Capital started coverage on Eloxx Pharmaceuticals in a research note on Wednesday, July 22nd. They issued an “outperform” rating and a $40.00 target price on the stock. Guggenheim reaffirmed a “buy” rating and issued a $43.00 price target on shares of Eloxx Pharmaceuticals in a research note on Monday, August 24th. Finally, Leerink Partners set a $32.00 price objective on shares of Eloxx Pharmaceuticals and gave the stock an “outperform” rating in a research note on Friday.

Eloxx Pharmaceuticals Stock Performance

Shares of NASDAQ ELOX traded down $0.31 during mid-day trading on Friday, reaching $17.24. The company had a trading volume of 2,850 shares, compared to its average volume of 50,901. The stock has a market capitalization of $69.65 million, a PE ratio of -11.19 and a beta of -1,862.26. The business has a 50-day moving average price of $15.80. Eloxx Pharmaceuticals has a 1-year low of $8.20 and a 1-year high of $23.40.

Eloxx Pharmaceuticals (NASDAQ:ELOX) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.66) earnings per share (EPS) for the quarter.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc was a clinical-stage biopharmaceutical company focused on developing therapies for genetic diseases caused by nonsense mutations, which can prevent cells from producing functional proteins. The company’s research platform centered on ribosome modulation, an approach intended to encourage cells to read through certain premature stop signals in genetic instructions.

Its lead product candidate, ELX-02, was an investigational small-molecule therapy designed to promote the production of full-length proteins in diseases associated with nonsense mutations.